Advertisement
ADVANCED SEARCH

This Article Figures Only Full Text Full Text (PDF) Résumé Online Appendices Submit a response View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barbui, C. Articles by Cipriani, A. Search for Related Content PubMed PubMed Citation Articles by Barbui, C., MD Articles by Cipriani, A., MD Related Collections Drugs: psychiatry Suicide Mood disorders (including depression) Related Articles

Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials

From the Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, World Health Organization Collaborating Centre for Research and Training in Mental Health (Barbui, Cipriani), University of Verona, Verona, Italy; and the Department of Psychiatry and Cognitive–Behavioral Medicine (Furukawa), Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Japan

Correspondence to: Dr. Corrado Barbui, Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Piazzale Scuro 10, 37134 Verona, Italy; fax +39-045-585871 (for the World Health Organization Collaborating Centre for Research and Training in Mental Health); corrado.barbui{at}univr.it

Background: Concern has been raised about the efficacy of antidepressant therapy for major depression in adults. We undertook a systematic review of published and unpublished clinical trial data to determine the effectiveness and acceptability of paroxetine.

Methods: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register, the Cochrane Central Register of Controlled Trials, the GlaxoSmithKline Clinical Trial Register, MEDLINE and EMBASE up to December 2006. Published and unpublished randomized trials comparing paroxetine with placebo in adults with major depression were eligible for inclusion. We selected the proportion of patients who left a study early for any reason as the primary outcome measure because it represents a hard measure of treatment effectiveness and acceptability.

Results: We included in our review 29 published and 11 unpublished clinical trials, with a total of 3704 patients who received paroxetine and 2687 who received with placebo. There was no difference between paroxetine and placebo in terms of the proportion of patients who left the study early for any reason (random effect relative risk [RR] 0.99, 99% confidence interval [CI] 0.88–1.11). Paroxetine was more effective than placebo, with fewer patients who did not experience improvement in symptoms of at least 50% (random effect RR 0.83, 99% CI 0.77–0.90). Significantly more patients in the paroxetine group than in the placebo group left their respective studies because of side effects (random effect RR 1.77, 95% CI 1.44–2.18) or experienced suicidal tendencies (odds ratio 2.55, 95% CI 1.17–5.54).

Interpretation: Among adults with moderate to severe major depression in the clinical trials we reviewed, paroxetine was not superior to placebo in terms of overall treatment effectiveness and acceptability. These results were not biased by selective inclusion of published studies.

This article has been cited by other articles:

				C. Barbui, A. Cipriani, T. A Furukawa, G. Salanti, J. P T Higgins, R. Churchill, N. Watanabe, A. Nakagawa, I. M Omori, and J. R Geddes Making the best use of available evidence: the case of new generation antidepressants: A response to: Are all antidepressants equal? Evid. Based Ment. Health, November 1, 2009; 12(4): 101 - 104. [Full Text] [PDF]

				J. B. Fontenele, L. K. A. M. Leal, and F. H. C. Felix Comment on: Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies & Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy Rheumatology, March 1, 2009; 48(3): 322 - 323. [Full Text] [PDF]

				C. Barbui MD, E. Esposito MD, and A. Cipriani MD Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies Can. Med. Assoc. J., February 3, 2009; 180(3): 291 - 297. [Abstract] [Full Text] [PDF]

				K A Wittkampf, M van Zwieten, F T. Smits, A H Schene, J Huyser, and H C van Weert Patients' view on screening for depression in general practice Fam. Pract., December 1, 2008; 25(6): 438 - 444. [Abstract] [Full Text] [PDF]

				D. Deshauer MD MSc, D. Moher PhD, D. Fergusson PhD, E. Moher BA, M. Sampson MLIS, and J. Grimshaw MD PhD Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials Can. Med. Assoc. J., May 6, 2008; 178(10): 1293 - 1301. [Abstract] [Full Text] [PDF]

				M. M. Finkelstein PhD MDCM Effectiveness of selective serotonin reuptake inhibitors Can. Med. Assoc. J., April 22, 2008; 178(9): 1185 - 1185. [Full Text] [PDF]

				C. Barbui MD, T. A. Furukawa MD PhD, and A. Cipriani MD Effectiveness of selective serotonin reuptake inhibitors Can. Med. Assoc. J., April 22, 2008; 178(9): 1185 - 1186. [Full Text] [PDF]

eLetters:

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-2008, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.